Reactive Oxygen Species Reprogram Macrophages to Suppress Antitumor Immune Response Through the Exosomal MiR-155-5p/PD-L1 Pathway
Overview
Authors
Affiliations
Background: Cancer cells have an imbalance in oxidation-reduction (redox) homeostasis. Understanding the precise mechanisms and the impact of the altered redox microenvironment on the immunologic reaction to tumors is limited.
Methods: We isolated exosomes from ovarian cancer cells through ultracentrifuge and characterized by Western-blots and Nanoparticle Tracking Analysis. 2D, 3D-coculture tumor model, and 3D live cell imaging were used to study the interactions between tumor cells, macrophages and CD3 T cells in vitro. The role of exosomal miR-155-5p in tumor growth was evaluated in xenograft nude mice models and immune-competent mice models. Flow cytometry and flow sorting were used to determine the expression levels of miR-155-5p and PD-L1 in ascites and splenic macrophages, and the percentages of CD3 T cells subpopulations.
Results: The elevation of reactive oxygen species (ROS) greatly downregulated exosomal miR-155-5p expression in tumor cells. Neutralization of ROS with N-acetyl-L-cysteine (NAC) increased the levels of miR-155-5p in tumor exosomes that were taken up by macrophages, leading to reduction of macrophage migration and tumor spheroid infiltration. We further found that programmed death ligand 1 (PD-L1) is a functional target of miR-155-5p. Co-culture of macrophages pre-treated with NAC-derived tumor exosomes or exosomal miR-155-5p with T-lymphocytes leading to an increased percentage of CD8 T-lymphocyte and a decreased CD3 T cell apoptosis through PD-L1 downregulation. Tumor growth in nude mice was delayed by treatment with NAC-derived tumor exosomes. Delivery of tumor exo-miR-155-5p in immune-intact mice suppressed ovarian cancer progression and macrophage infiltration, and activated CD8 T cell function. It is of note that exo-miR-155-5p inhibited tumor growth more potently than the PD-L1 antibody, suggesting that in addition to PD-L1, other pathways may also be targeted by this approach.
Conclusions: Our findings demonstrate a novel mechanism, ROS-induced down-regulation of miR-155-5p, by which tumors modulate the microenvironment that favors tumor growth. Understanding of the negative impact of ROS on the tumor immune response will improve current therapeutic strategies. Targeting miR-155-5p can be an alternative approach to prevent formation of an immunosuppressive TME through downregulation of PD-L1 and other immunosuppressive factors.
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.
Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.
PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.
Xiong Z, Huang Y, Cao S, Huang X, Zhang H Front Immunol. 2025; 16:1542326.
PMID: 40013141 PMC: 11860879. DOI: 10.3389/fimmu.2025.1542326.
Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities.
Liu C, Yin Q, Wu Z, Li W, Huang J, Chen B J Inflamm Res. 2025; 18:895-909.
PMID: 39867950 PMC: 11762012. DOI: 10.2147/JIR.S503479.
Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease.
Mao Y, Chen H, Zhu W, Ni S, Luo S, Tang S J Inflamm Res. 2025; 18:883-894.
PMID: 39867947 PMC: 11760270. DOI: 10.2147/JIR.S498340.
Li Y, Yang Q, Li D, Li W, Men W Int J Nanomedicine. 2025; 20():653-667.
PMID: 39835179 PMC: 11745065. DOI: 10.2147/IJN.S502363.